« Return to News | Clinical Intelligence

FDA approves Bionomics’ phase I/II ovarian cancer trial

Monday, March 26, 2012 02:19 PM

Bionomics Limited, an international biotech based in Thebarton, Australia, has gained approval from the FDA to proceed with its clinical trial of BNC105 in women with ovarian cancer.

Bionomics anticipated the approval and has already prepared much of the trial, with expected initiation in the next quarter. The phase I/II trial will evaluate BNC105 in combination with carboplatin and gemcitabine in a multi-centre trial in Australia and the U.S.

BNC105 is a Vascular Disruption Agent (VDA) that rapidly shuts down existing and new tumor blood vessels with no effect on normal blood vessels. Preclinical data has indicated that all solid tumor types, including breast, prostate and lung cancers, are susceptible to the VDA effect of BNC105 and that the compound also potently inhibits the growth of a broad range of cancer cells in culture.

In addition, BNC105 is currently under evaluation in combination with the mTOR inhibitor Everolimus (Afinitor), in a U.S. multi-center phase II clinical trial in patients with metastatic renal cell carcinoma (kidney cancer). More than 21 U.S.-based trial sites have been activated to date and the combination of BNC105 and Afinitor has been shown to be safe and well tolerated. Enrollment in the trial is due for completion at the end of 2012.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.